Betnovate

Basic Betnovate information

• INN (international nonproprietary name): Betamethasone valerate.
• Brand names available in the United Kingdom: Betnovate (cream/ointment 0.1% usually in 30g or 100g tubes).
• ATC code: D07AC01 (Corticosteroids, strong, group III, dermatological preparations).
• Forms and strengths: cream 0.1% (tubes 30g, 100g); ointment 0.1% (tubes 30g, 100g); lotion/scalp application 0.1%.
• Manufacturers in the United Kingdom: GlaxoSmithKline (GSK).
• Registration status in the United Kingdom: MHRA approved prescription medicine.
• OTC / Rx classification: Prescription only (Rx).

Legal status and availability in the UK

Betnovate is a prescription-only medicine (POM) in the UK and is supplied on NHS or private prescription.

In our online pharmacy, Betnovate is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Patients commonly ask: “Will Betnovate clear my flare quickly?”

Betnovate is a commonly prescribed group‑III (potent) topical steroid for moderate eczema and localised psoriasis flares.

Clinical improvement is usually seen within 7–14 days when betamethasone valerate cream or ointment is used correctly.

Short‑term effectiveness is good, but relapse is more likely when patients abruptly stop after prolonged use.

Success depends closely on correct application and adherence; fear of skin thinning is a common barrier.

How to use (stepwise)

• Apply a thin film once to twice daily to affected areas as directed by prescriber.
• Use fingertip‑unit guidance for dose control (one fingertip unit covers roughly two adult palm‑sized areas).
• Expect improvement within 3–7 days and clearer response by two weeks.
• Stop or taper per GP/pharmacist instructions; do not exceed prescribed duration (rarely over 4 weeks).
• Seek review if lesions worsen, signs of infection appear, or new symptoms develop.

Indications and expanded uses — MHRA‑approved and common off‑label practices

Patients wonder which conditions Betnovate is licensed for and when specialists may use it off‑label.

• MHRA‑approved indications: inflammatory dermatoses responsive to potent corticosteroids — eczema, plaque psoriasis, lichen planus and contact dermatitis.
• Typical NHS practice restricts routine facial or intertriginous prescriptions and specifies limited duration with review.
• Off‑label use (private/specialist clinics): focal alopecia areata and prurigo nodularis under specialist supervision only.

Clinician checklist for primary care

• Confirm diagnosis and document indication on prescription.
• Specify potency (betamethasone valerate 0.1%), formulation and maximum duration (typically 1–2 weeks, rarely >4).
• Advise fingertip‑unit dosing and arrange pharmacist or GP review if prolonged therapy is anticipated.
• Avoid in suspected viral, fungal or untreated bacterial skin infections; consider combination products only if secondary infection present and appropriate.
• Explain off‑label rationale and set clear step‑down plan to emollients or a milder steroid.

Composition and brand landscape — active ingredients, manufacturers and pack formats

Patients often ask for brand alternatives and pack sizes when seeking rapid relief.

INN: betamethasone valerate, marketed widely as Betnovate in the UK by GlaxoSmithKline (GSK).

Generic betamethasone valerate products are also available.

• Excipients to flag for allergies: specific excipients vary by manufacturer — check the pack leaflet; if not specified on the prescription, ask the dispensing pharmacist.
• Combination creams containing neomycin or clioquinol have extra risks such as contact sensitivity and ototoxicity (neomycin) and should be used only when clearly indicated.

Contraindications and special precautions — high‑risk groups and daily‑life restrictions

Many patients worry about whether Betnovate is safe for them, especially if pregnant, elderly or treating a child.

1. Absolute contraindications:
   • Hypersensitivity to betamethasone valerate or any excipient.
   • Viral, fungal or untreated bacterial skin infections (for example herpes simplex, chickenpox, impetigo).
   • Rosacea, acne vulgaris, perioral dermatitis, and tuberculous skin lesions.
   • Not for ophthalmic use — avoid the eyes.
2. Relative contraindications (require monitoring):
   • Large‑area or prolonged therapy due to risk of systemic effects such as HPA‑axis suppression.
   • Infants and the elderly — monitor closely for skin thinning and irritation.
   • Impaired skin barrier and intertriginous areas — use with caution.
   • Pregnancy and lactation — use only if benefits outweigh risks and under supervision.

Storage and regulatory notes: Store at 15–25°C and keep out of reach of children.

Rx status: prescription-only medicine in the UK.

Dosage guidelines — NHS‑recommended regimens and adjustments for special populations

People commonly ask: “How much should I use and how do fingertip units work?”

Step‑by‑step application

• Wash and dry the area gently before application.
• Squeeze a thin film on the fingertip — one fingertip unit covers approximately two adult palm‑sized areas.
• Apply once or twice daily as prescribed and rub in gently.
• Use the smallest effective amount, especially for children and the elderly.
• Do not occlude unless advised by a clinician and for short, supervised periods only.

For prolonged or large‑area therapy arrange dermatology review and consider HPA‑axis monitoring if systemic exposure is likely.

Interactions overview — drug, food and report‑level signals (MHRA Yellow Card)

Patients ask whether Betnovate interacts with other medicines or with food.

Topical betamethasone valerate has minimal direct food interactions.

Systemic interactions are rare but possible if significant percutaneous absorption occurs after extensive or occlusive use.

• MHRA Yellow Card reports mainly describe systemic steroid signs linked to misuse or prolonged use rather than classic pharmacokinetic drug–drug interactions.
• Advise patients there are no alcohol or dietary restrictions related to topical Betnovate use.

Comparable medicines and preferences — escalation and NHS choices

GPs and patients often ask whether Betnovate is the right potency or whether to step up or down.

Betamethasone valerate (group III) sits between moderate and super‑potent steroids.

Clobetasol propionate (Dermovate) is a super‑high potency option for more severe disease, while mometasone furoate (Elocon) is an intermediate choice and hydrocortisone is for mild/maintenance use.

• Patient checklist: If you need fast symptom control, Betnovate may be suitable for short bursts, but expect a plan to step down to an emollient or milder steroid.

Frequently asked questions

Q1: How quickly does Betnovate work?

A: Redness and itching usually reduce within 3–7 days and clearer improvement by two weeks when used as directed.

Q2: Can I use Betnovate on my face or in children?

A: Routine facial application is not advised under MHRA guidance and children require caution — use the smallest amount for the shortest period and follow GP or pharmacist guidance.

Q3: What if I miss a dose or use too much?

A: Missed doses can be applied when remembered; do not double up.

A: Excessive use, especially over large areas or under occlusion, risks systemic effects including HPA‑axis suppression — contact your GP or NHS 111 if concerned.

Q4: Can I buy Betnovate without a prescription?

A: No — Betnovate is a prescription-only medicine in the UK and should be obtained via GP, private prescription or NHS e‑prescription services.

Definitions

• HPA axis: Hypothalamic‑pituitary‑adrenal axis — the body system that can be suppressed by systemic corticosteroid exposure.
• Occlusion: Covering treated skin (for example with a dressing) which increases absorption and should only be used under medical advice.

Report side effects to the MHRA Yellow Card scheme and seek immediate advice for systemic symptoms.

Guidelines for proper use — pharmacist counselling script, patient leaflets, safety netting

Pharmacists should lead with clear, practical instructions and demonstration.

Key patient information

• Why this medicine: For short‑term control of inflammation in eczema, psoriasis and dermatitis.
• How to use: Apply a thin film once to twice daily; use fingertip units; expect improvement within days.
• Duration: 1–2 weeks typically; rarely above 4 weeks unless reviewed by a clinician.
• Warnings: Avoid face, groin and axillae unless instructed; do not occlude unless told to do so.
• When to seek help: Worsening rash, signs of infection, systemic symptoms or suspected overdose.
• Storage: 15–25°C; keep out of reach of children.

Pharmacist counselling points

• Confirm the condition and show the patient how much to apply using a fingertip unit demonstration.
• State the exact duration and advise on a taper plan if appropriate.
• Ask about pregnancy, age of household members and concurrent steroid use, and flag if large areas are treated.
• Provide safety‑netting: contact GP, NHS 111 or return to the pharmacy for worsening or suspected infection.

For children and older adults record a baseline skin assessment and schedule an earlier review.

Encourage Yellow Card reporting for any suspected adverse reaction.

Delivery across the United Kingdom